Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 15Thoracic 8Genitourinary 8Breast 8Gastrointestinal 7Head & Neck 6Gynecologic 4Sarcoma 3Other solid neoplasm 2Lymphoid 2CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Lymphoma 7Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, T-Cell, Cutaneous 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × durvalumab × Lymphoid × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡